Skip to main content
. 2016 Oct 31;4(4):24. doi: 10.3390/biomedicines4040024

Table 2.

Percent change of 18F-fluoromisonidazole (FMISO) metrics between imaging time points.

Patient # 1 2 3 4 Mean Standard Deviation
Hypoxic Volume −19.2 −97.1 −86.5 0 −50.75 48.25
Hypoxic Volume T/Bmean −3.06 −18.2 5.78 NA −5.16 10.23
Hypoxic Volume T/Bmax −13.1 −31.1 −28.9 NA −24.37 14.58
FLAIR Volume −59.9 3.26 7.32 −14.1 −15.86 30.80
FLAIR T/Bmean 2.51 −22.6 −1.09 14.1 −1.77 15.32
FLAIR T/Bmax −27.9 −46.7 −51.4 62.1 −15.98 53.03
Enhancing Volume −80.4 −96.9 −95.8 −41.4 −78.63 25.93
Enhancing T/Bmean 34.1 −33.3 −1.92 11.5 2.60 28.17
Enhancing T/Bmax −27.9 −46.7 −51.4 62.1 −15.98 53.03
Lesion rCBV −22.0 −50.1 −46.2 −0.04 −30.5 17.3
Lesion rCBF −18.4 −12.1 −0.04 −0.01 −0.22 0.08

Reference: NA, not applicable; T/B, tissue to background FMISO uptake ratio; max, maximum. Negative value represents decrease in percent change from baseline. Lesion rCBV and rCBF calculated at baseline (enhancing mass) and follow-up exam (reduced diffusion mass when present, or T2 hyperintense lesion when no reduced diffusion mass was present).